It's "one example of AI that we don't have to fear, that we can be really excited about," is how one doctor puts it. He's ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Studies show how some plant foods can reduce inflammation, prevent flare-ups and even lower surgery risks for those with ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

Inflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team ...

Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

A new study suggests AI can predict premature death among people who have inflammatory bowel disease, also known as Crohn's ...

While symptoms of Crohn’s disease, such as abdominal pain, diarrhea, fatigue, and bloating can disrupt daily life, they don’t ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...